Balance Sheet
Cash Flow Statement
Beginning Cash BalanceBeginning Cash BalanceCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationDepreciation ExpenseEBIATLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingWages, Salaries and Other
Ratios

Calidi Biotherapeutics (CLDI) Long-Term Debt Repayments (2023 - 2025)

Calidi Biotherapeutics' quarterly Long-Term Debt Repayments came in at $200000.0 in Q1 2025, up 769.57% year-on-year from $23000.0 in Q1 2024, and up 191.74% quarter-over-quarter from -$218000.0 in Q4 2024.

Calidi Biotherapeutics has reported Long-Term Debt Repayments for 3 years, with the latest figure at $200000.0 in Q1 2025.

  • For the quarter ending Q1 2025, Long-Term Debt Repayments rose 769.57% year-over-year to $200000.0; the trailing twelve-month figure through Dec 2025 stood at $200000.0 (up 143.9% YoY), and the FY2025 full-year result was $200000.0, up 143.9% from the prior year.
  • Long-Term Debt Repayments for Q1 2025 stood at $200000.0, up from -$218000.0 in the prior quarter.
  • The five-year high for Long-Term Debt Repayments was $255000.0 in Q3 2024, with the low at -$218000.0 in Q4 2024.
  • Average Long-Term Debt Repayments over 3 years is $42555.6, with a median of $22000.0 recorded in 2024.
  • Peak annual rise in Long-Term Debt Repayments reached 1400.0% in 2024, while the deepest fall reached 554.17% in 2024.
  • Tracing CLDI's Long-Term Debt Repayments over 3 years: stood at $48000.0 in 2023, then plunged by 554.17% to -$218000.0 in 2024, then jumped by 191.74% to $200000.0 in 2025.
  • The last three Long-Term Debt Repayments figures came in at $200000.0 (Q1 2025), -$218000.0 (Q4 2024), and $255000.0 (Q3 2024), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Repayments (Qtr)
1 Quantum Biopharma 1,638,563.89 Bn 1,638,563.89 Bn - -
2 Alterity Therapeutics 767,934.24 Bn 767,934.20 Bn - -
3 Legend Biotech 2,937.00 Bn 2,936.10 Bn 242.10 Mn -
4 Nanobiotix 2,282.79 Bn 2,282.72 Bn - -
5 Akari Therapeutics 2,169.69 Bn 2,169.69 Bn - -
6 Vertex Pharmaceuticals 110.41 Bn 103.16 Bn 2.59 Bn -
7 Regeneron Pharmaceuticals 66.44 Bn 57.69 Bn 3.31 Bn -
8 Evaxion A 65.44 Bn 65.42 Bn - -
9 Alnylam Pharmaceuticals 39.53 Bn 36.52 Bn 959.66 Mn -
10 Calidi Biotherapeutics - - - -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2025 200,000.00
Mar 31, 2025 200,000.00
Dec 31, 2024 -218,000.00
Dec 31, 2024 -218,000.00
Sep 30, 2024 255,000.00
Sep 30, 2024 255,000.00
Jun 30, 2024 22,000.00
Jun 30, 2024 22,000.00
Mar 31, 2024 23,000.00
Mar 31, 2024 23,000.00
Dec 31, 2023 48,000.00
Dec 31, 2023 48,000.00
Sep 30, 2023 17,000.00
Sep 30, 2023 17,000.00
Jun 30, 2023 17,000.00
Jun 30, 2023 17,000.00
Mar 31, 2023 19,000.00
Mar 31, 2023 19,000.00